Literature DB >> 11717709

Risk factors for ovarian failure in patients with systemic lupus erythematosus.

M M Medeiros1, V A Silveira, A P Menezes, R C Carvalho.   

Abstract

The aim of the present study was to identify the risk factors for ovarian failure in patients with systemic lupus erythematosus. Seventy-one women aged 17 to 45 years with systemic lupus erythematosus were studied. Patients were interviewed and their medical records reviewed. Demographic characteristics, clinical and serologic profiles, and menstrual and obstetric histories were recorded. Disease activity was measured by the systemic lupus erythematosus disease activity index. Serum FSH, LH, estradiol, progesterone, TSH, prolactin, and antimicrosomal and antithyroglobulin antibodies were measured. Patients who developed ovarian failure were compared to those who did not. Ovarian failure occurred in 11 patients (15.5%) and nine had premature menopause (11.3%). Cyclophosphamide administration and older patient age were found to be associated with ovarian failure. The cumulative cyclophosphamide dose was significantly higher in patients with ovarian failure than in those without this condition (18.9 vs 9.1 g; P = 0.04). The relative risk for ovarian failure in patients with cumulative cyclophosphamide dose higher than 10 g was 3.2. TSH levels were high in 100% of patients with ovarian failure who had received pulse cyclophosphamide. Ovarian failure, and premature menopause in particular, is common in patients with systemic lupus erythematosus, with the most important risk factors being cyclophosphamide dose and age. Thyroid problems may be another risk factor for ovarian failure in patients with lupus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717709     DOI: 10.1590/s0100-879x2001001200008

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  8 in total

1.  Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.

Authors:  W Marder; W J McCune; L Wang; J J Wing; S Fisseha; D S McConnell; G M Christman; E C Somers
Journal:  Gynecol Endocrinol       Date:  2012-02-02       Impact factor: 2.260

2.  Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis.

Authors:  Rajiva Gupta; S Deepanjali; M M Thabah; P Kaur; S Gupta
Journal:  Rheumatol Int       Date:  2009-01-24       Impact factor: 2.631

3.  Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.

Authors:  Gabriela Schmajuk; Edward Yelin; Eliza Chakravarty; Lorene M Nelson; Pantelis Panopolis; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

4.  Nonmalignant diseases and treatments associated with primary ovarian failure: an expanded role for fertility preservation.

Authors:  Jennifer Hirshfeld-Cytron; Clarisa Gracia; Teresa K Woodruff
Journal:  J Womens Health (Larchmt)       Date:  2011-08-09       Impact factor: 2.681

Review 5.  Menopause and Rheumatic Disease.

Authors:  Mitali Talsania; Robert Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2017-05       Impact factor: 2.670

6.  Prevalence and risk factors of vertebral compression fractures in female SLE patients.

Authors:  Katarina Almehed; Szabolcs Hetényi; Claes Ohlsson; Hans Carlsten; Helena Forsblad-d'Elia
Journal:  Arthritis Res Ther       Date:  2010-08-02       Impact factor: 5.156

7.  Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study.

Authors:  X W Zhang; Chun Li; X X Ma; J X Zhao; Yuan An; Shuang Liu; Yan Li; Z G Li
Journal:  Clin Rheumatol       Date:  2014-04-18       Impact factor: 2.980

8.  Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the GOAL study.

Authors:  Jessica H Knight; Penelope P Howards; Jessica B Spencer; Katina C Tsagaris; Sam S Lim
Journal:  Lupus Sci Med       Date:  2016-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.